- Home
- BAX vs NBIX Comparison
BAX vs NBIX Comparison
Compare BAX & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAX
- NBIX
- Stock Information
- Founded
- BAX 1931
- NBIX 1992
- Country
- BAX United States
- NBIX United States
- Employees
- BAX N/A
- NBIX N/A
- Industry
- BAX Medical/Dental Instruments
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BAX Health Care
- NBIX Health Care
- Exchange
- BAX Nasdaq
- NBIX Nasdaq
- Market Cap
- BAX 15.1B
- NBIX 13.7B
- IPO Year
- BAX N/A
- NBIX 1996
- Fundamental
- Price
- BAX $30.97
- NBIX $143.26
- Analyst Decision
- BAX Hold
- NBIX Buy
- Analyst Count
- BAX 10
- NBIX 22
- Target Price
- BAX $40.90
- NBIX $164.81
- AVG Volume (30 Days)
- BAX 4.8M
- NBIX 995.1K
- Earning Date
- BAX 02-06-2025
- NBIX 02-05-2025
- Dividend Yield
- BAX 3.37%
- NBIX N/A
- EPS Growth
- BAX N/A
- NBIX 97.40
- EPS
- BAX 0.21
- NBIX 3.73
- Revenue
- BAX $15,062,000,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- BAX N/A
- NBIX $27.07
- Revenue Next Year
- BAX $6.57
- NBIX $17.14
- P/E Ratio
- BAX $145.42
- NBIX $38.43
- Revenue Growth
- BAX 32.37
- NBIX 25.72
- 52 Week Low
- BAX $28.34
- NBIX $110.95
- 52 Week High
- BAX $44.01
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- BAX 55.98
- NBIX 66.20
- Support Level
- BAX $30.12
- NBIX $138.66
- Resistance Level
- BAX $31.20
- NBIX $144.24
- Average True Range (ATR)
- BAX 0.71
- NBIX 3.23
- MACD
- BAX 0.35
- NBIX 0.07
- Stochastic Oscillator
- BAX 91.96
- NBIX 82.29
About BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter has signed an agreement to sell its kidney care tools by early 2025.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.